Financing ·
Enveric Biosciences, Inc. filed a prospectus supplement on June 9, 2026, to offer an additional $2,425,000 of common…
ENVBEnveric Biosciences, Inc.
Enveric Biosciences, Inc. filed a prospectus supplement on June 9, 2026, to offer an additional $2,425,000 of common stock under its existing At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. The company has previously sold an aggregate of $4,483,711.04 through this agreement. Enveric Biosciences, Inc. is a biotechnology company focused on developing novel drug delivery technologies and therapeutics.